Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0002094682-25-000001
Filing Date
2025-10-30
Accepted
2025-10-30 18:48:43
Documents
15

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 32348
2 JOINT FILING AGREEMENT jfa.pdf EX-1 117474
3 POA BUTTERWORTH butterworth.pdf EX-2 53188
4 POA R JONES richjones2.pdf EX-3 35291
5 POA E JONES ejones2.pdf EX-4 84916
6 POA DOWNING downing3.pdf EX-5 84118
7 POA KOTEY kotey4.pdf EX-7 168030
8 POA COLE cole4.pdf EX-8 165316
9 POA CHAUDREY chaudrey2.pdf EX-9 175244
10 POA BABB babb2.pdf EX-10 166274
11 POA CRAIG craig6.pdf EX-11 172579
12 POA NICHOLLS nicholls3.pdf EX-12 168352
13 POA WARE ware2.pdf EX-13 84310
14 POA HENNESSY hennessy2.pdf EX-17 167895
15 POA DOUGLAS douglas.pdf EX-19 35449
  Complete submission text file 0002094682-25-000001.txt   2346748
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-79364 | Film No.: 251437475
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 6 THE PENINSULA PANORAMA ROAD POOLE United Kingdom BH13 7RS
Business Address
Price Adrian (Filed by) CIK: 0002094682 (see all company filings)

Type: SCHEDULE 13D